Diyong Xu
Partner·OrbiMed
Diyong Xu is a Partner on OrbiMed's Private Equity team and has been with the firm since 2012. Before OrbiMed, he was an investment banking analyst in Lazard's healthcare group, advising biotech, diagnostics and pharma clients on M&A, financing and strategic transactions. Public company and portfolio-company sources list him as a director of Q32 Bio, Frontera Therapeutics and Sirius Therapeutics.
See the rest of Diyong Xu's profile.
Deal history, investment focus, outreach angles and the rest of the background. One email, no password — we send a link and you land right back here.